Downregulated microRNA-510-5p acts as a tumor suppressor in renal cell carcinoma

Chen,Duqun; Li,Yuchi; Yu,Zuhu; Li,Yifan; Su,Zhengming; Ni,Liangchao; Yang,Shangqi; Gui,Yaoting; Lai,Yongqing

doi:10.3892/mmr.2015.3704

Downregulated microRNA-510-5p acts as a tumor suppressor in renal cell carcinoma

Authors:
- Duqun Chen
- Yuchi Li
- Zuhu Yu
- Yifan Li
- Zhengming Su
- Liangchao Ni
- Shangqi Yang
- Yaoting Gui
- Yongqing Lai
View Affiliations

Affiliations: Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China, The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
Published online on: April 29, 2015 https://doi.org/10.3892/mmr.2015.3704
Pages: 3061-3066

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)-510-5p has been demonstrated to be involved in a number of types of malignancy; however, the function of miR‑510‑5p in renal cancer remains unclear. The present study aimed to determine the expression of miR‑510‑5p in renal cell carcinoma (RCC) specimens and analyzed the impact of miR‑510‑5p on renal cancer by 3-(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide, wound scratch and apoptosis assays. The results showed that miR‑510‑5p was significantly downregulated in RCC specimens compared with normal renal specimens. Overexpression of miR‑510‑5p by synthetic mature mimics reduced cell proliferation and migration and induced an increase in cell apoptosis, indicating that miR‑510‑5p may act as a tumor suppressor in RCC. The present study firstly revealed that downregulated miR‑510‑5p functioned as a tumor suppressor by reducing cellular proliferation and migration, and inducing apoptosis in RCC. Further research is required to define target genes of miR‑510‑5p to determine the cellular mechanism of miR‑510‑5p in the carcinogenesis of RCC.

View Figures

View References

1	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
2	Hofmann HS, Neef H, Krohe K, Andreev P and Silber RE: Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 48:77–81. 2005. View Article : Google Scholar : PubMed/NCBI
3	Arsanious A, Bjarnason GA and Yousef GM: From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer. 8:202009. View Article : Google Scholar : PubMed/NCBI
4	Wood CG: Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. J Surg Oncol. 94:264–265. 2006. View Article : Google Scholar : PubMed/NCBI
5	Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
6	Patel C, Ahmed A and Ellsworth P: Renal cell carcinoma: a reappraisal. Urol Nurs. 32:182–190. 2012.PubMed/NCBI
7	Maroto P and Rini B: Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res. 20:2060–2071. 2014. View Article : Google Scholar : PubMed/NCBI
8	Aqeilan RI, Calin GA and Croce CM: miR-15a and miR-16–1 in cancer: discovery, function and future perspectives. Cell Death Differ. 17:215–220. 2010. View Article : Google Scholar
9	White NM, Khella HW, Grigull J, et al: miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer. 105:1741–1749. 2011. View Article : Google Scholar : PubMed/NCBI
10	Cho WC: OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
11	Tiwari M: Microarrays and cancer diagnosis. J Cancer Res Ther. 8:3–10. 2012. View Article : Google Scholar : PubMed/NCBI
12	Perez-Diez A, Morgun A and Shulzhenko N: Microarrays for cancer diagnosis and classification. Adv Exp Med Biol. 593:74–85. 2007.PubMed/NCBI
13	Shenouda SK and Alahari SK: MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
14	Koberle V, Kronenberger B, Pleli T, et al: Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 49:3442–3449. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhao A, Li G, Péoc’h M, Genin C and Gigante M: Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 94:115–120. 2013. View Article : Google Scholar
16	Patnaik SK, Kannisto E, Knudsen S and Yendamuri S: Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 70:36–45. 2010. View Article : Google Scholar
17	Guo QJ, Mills JN, Bandurraga SG, et al: MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer. Breast Cancer Res. 15:R702013. View Article : Google Scholar : PubMed/NCBI
18	Yu X, Zhang X, Bi T, et al: MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biol. 34:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
19	Chen W, Tang Z, Sun Y, et al: miRNA expression profile in primary gastric cancers and paired lymph node metastases indicates that miR-10a plays a role in metastasis from primary gastric cancer to lymph nodes. Exp Ther Med. 3:351–356. 2012.PubMed/NCBI
20	Guinan P, Sobin LH, Algaba F, et al: TNM staging of renal cell carcinoma: Workgroup No. 3 Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 80:992–993. 1997. View Article : Google Scholar : PubMed/NCBI
21	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
22	White NM, Bao TT, Grigull J, et al: miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol. 186:1077–1083. 2011. View Article : Google Scholar : PubMed/NCBI
23	Liu H, Brannon AR, Reddy AR, et al: Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol. 4:512010. View Article : Google Scholar : PubMed/NCBI
24	Sana J, Faltejskova P, Svoboda M and Slaby O: Novel classes of non-coding RNAs and cancer. J Transl Med. 10:1032012. View Article : Google Scholar : PubMed/NCBI
25	Koscianska E, Baev V, Skreka K, et al: Prediction and preliminary validation of oncogene regulation by miRNAs. BMC Mol Biol. 8:792007. View Article : Google Scholar : PubMed/NCBI
26	Volinia S, Galasso M, Costinean S, et al: Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 20:589–599. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kefas B, Godlewski J, Comeau L, et al: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 68:3566–3572. 2008. View Article : Google Scholar : PubMed/NCBI
28	Mikhaylova O, Stratton Y, Hall D, et al: VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell. 21:532–546. 2012. View Article : Google Scholar : PubMed/NCBI
29	Dey N, Das F, Ghosh-Choudhury N, et al: microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS One. 7:e373662012. View Article : Google Scholar : PubMed/NCBI
30	White NM, Bao TT, Grigull J, et al: miRNA profiling for clear cell renal cell carcinoma: Biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol. 186:1077–1083. 2011. View Article : Google Scholar : PubMed/NCBI
31	Liu H, Brannon AR, Reddy AR, et al: Identifying mRNA targets of microRNA dysregulated in cancer: With application to clear cell renal cell carcinoma. BMC Syst Biol. 4:512010. View Article : Google Scholar : PubMed/NCBI
32	Krzeslak A: Akt kinase: a key regulator of metabolism and progression of tumors. Postepy Hig Med Dosw (Online). 64:490–503. 2010.In Polish.
33	Agarwal E, Brattain MG and Chowdhury S: Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
34	Macher-Goeppinger S, Bermejo JL, Wagener N, et al: Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett. 301:203–211. 2011. View Article : Google Scholar : PubMed/NCBI
35	Sejima T, Morizane S, Hinata N, et al: Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy. Urol Int. 88:263–270. 2012. View Article : Google Scholar : PubMed/NCBI